{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Brucea javanica extract", "CK2", "IL-2", "Jurkat", "NF-\u03baB", "T-ALL"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "29966986", "DateCompleted": {"Year": "2018", "Month": "12", "Day": "14"}, "DateRevised": {"Year": "2021", "Month": "12", "Day": "04"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "07", "Day": "11"}], "Language": ["eng"], "ELocationID": ["10.1016/j.biopha.2018.06.164", "S0753-3322(18)30826-6"], "Journal": {"ISSN": "1950-6007", "JournalIssue": {"Volume": "106", "PubDate": {"Year": "2018", "Month": "Oct"}}, "Title": "Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie", "ISOAbbreviation": "Biomed Pharmacother"}, "ArticleTitle": "In vitro combinatorial anti-proliferative and immunosuppressive effects of Brucea javanica extract with CX-4945 and imatinib in human T-cell acute lymphoblastic leukemia cells.", "Pagination": {"StartPage": "403", "EndPage": "410", "MedlinePgn": "403-410"}, "Abstract": {"AbstractText": ["Since 1970, the isolated and identified components of Brucea javanica (L.) Merr. have been known to contain anticancer effects, particularly antileukemic effect. In this study, the inhibitory effect of Brucea javanica (BJ) on cell growth and inflammation was confirmed in human T-cell acute lymphocytic leukemia (T-ALL) cells, and its efficacy as an antileukemic agent was verified. Our results showed that BJ extract induced caspase-dependent apoptosis of T-ALL Jurkat cells through inhibition of the CK2-mediated signaling pathway, while exerting no significant cytotoxicity in normal peripheral blood mononuclear cells. Moreover, BJ extract suppressed the NF-\u03baB signaling pathway, thus, inhibiting the interleukin (IL)-2 expression induced by phorbol 12-myristate 13-acetate (PMA) and phytohemagglutinin (PHA). Notably, combined treatment with BJ extract plus CX-4945 or imatinib exerted enhanced inhibitory effects on T-ALL cell growth and IL-2 production. Overall, these results suggest that BJ extract can be a potent therapeutic herbal agent for T-ALL treatment and prevention of IL-2 mediated inflammatory immune responses."], "CopyrightInformation": "Copyright \u00a9 2018 Elsevier Masson SAS. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biomedical Laboratory Science, School of Medicine, Eulji University, Daejeon 34824, Republic of Korea. Electronic address: 96k620@gmail.com."}], "LastName": "Jung", "ForeName": "Jung-Il", "Initials": "JI"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biomedical Laboratory Science, School of Medicine, Eulji University, Daejeon 34824, Republic of Korea. Electronic address: fate1903@naver.com."}], "LastName": "Kim", "ForeName": "Se Young", "Initials": "SY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Integrated Material's Development, CHA Meditech Co., Ltd, Daejeon 34025, Republic of Korea. Electronic address: pky@chamc.co.kr."}], "LastName": "Park", "ForeName": "Kyeong-Yong", "Initials": "KY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Traditional Medicine, Ministry of Health, Vientiane Capital, Lao People's Democratic Republic. Electronic address: kmnkong@gmail.com."}], "LastName": "Sydara", "ForeName": "Kongmany", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "International Biological Material Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Republic of Korea. Electronic address: ethnolee@hanmail.net."}], "LastName": "Lee", "ForeName": "Sang Woo", "Initials": "SW"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, School of Medicine, Eulji University, Daejeon 34824, Republic of Korea. Electronic address: sakim@eulji.ac.kr."}], "LastName": "Kim", "ForeName": "Soon Ae", "Initials": "SA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biomedical Laboratory Science, School of Medicine, Eulji University, Daejeon 34824, Republic of Korea. Electronic address: yeon@eulji.ac.kr."}], "LastName": "Kim", "ForeName": "Jiyeon", "Initials": "J"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "France", "MedlineTA": "Biomed Pharmacother", "NlmUniqueID": "8213295", "ISSNLinking": "0753-3322"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "IL2 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Immunosuppressive Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Interleukin-2"}, {"RegistryNumber": "0", "NameOfSubstance": "NF-kappa B"}, {"RegistryNumber": "0", "NameOfSubstance": "Naphthyridines"}, {"RegistryNumber": "0", "NameOfSubstance": "Phenazines"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "8A1O1M485B", "NameOfSubstance": "Imatinib Mesylate"}, {"RegistryNumber": "C6RWP0N0L2", "NameOfSubstance": "silmitasertib"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Casein Kinase II"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Proto-Oncogene Proteins c-akt"}, {"RegistryNumber": "EC 3.4.22.-", "NameOfSubstance": "CASP3 protein, human"}, {"RegistryNumber": "EC 3.4.22.-", "NameOfSubstance": "CASP8 protein, human"}, {"RegistryNumber": "EC 3.4.22.-", "NameOfSubstance": "Caspase 3"}, {"RegistryNumber": "EC 3.4.22.-", "NameOfSubstance": "Caspase 8"}], "MeshHeadingList": [{"QualifierName": ["pharmacology"], "DescriptorName": "Antineoplastic Combined Chemotherapy Protocols"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["chemistry"], "DescriptorName": "Brucea"}, {"QualifierName": ["metabolism"], "DescriptorName": "Casein Kinase II"}, {"QualifierName": ["metabolism"], "DescriptorName": "Caspase 3"}, {"QualifierName": ["metabolism"], "DescriptorName": "Caspase 8"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Survival"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Imatinib Mesylate"}, {"QualifierName": ["isolation & purification", "pharmacology"], "DescriptorName": "Immunosuppressive Agents"}, {"QualifierName": ["metabolism"], "DescriptorName": "Interleukin-2"}, {"QualifierName": [], "DescriptorName": "Jurkat Cells"}, {"QualifierName": ["metabolism"], "DescriptorName": "NF-kappa B"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Naphthyridines"}, {"QualifierName": [], "DescriptorName": "Phenazines"}, {"QualifierName": [], "DescriptorName": "Phosphorylation"}, {"QualifierName": [], "DescriptorName": "Phytotherapy"}, {"QualifierName": ["isolation & purification", "pharmacology"], "DescriptorName": "Plant Extracts"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["drug therapy", "immunology", "metabolism", "pathology"], "DescriptorName": "Precursor T-Cell Lymphoblastic Leukemia-Lymphoma"}, {"QualifierName": ["metabolism"], "DescriptorName": "Proto-Oncogene Proteins c-akt"}, {"QualifierName": ["drug effects"], "DescriptorName": "Signal Transduction"}, {"QualifierName": [], "DescriptorName": "Time Factors"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2018", "Month": "2", "Day": "5"}, {"Year": "2018", "Month": "6", "Day": "25"}, {"Year": "2018", "Month": "6", "Day": "27"}, {"Year": "2018", "Month": "7", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "12", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "7", "Day": "4", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["29966986", "10.1016/j.biopha.2018.06.164", "S0753-3322(18)30826-6"]}}]}